Published in J Clin Pathol on August 10, 2007
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res (2015) 1.11
Evidence for oxidative stress in the developing cerebellum of the rat after chronic mild carbon monoxide exposure (0.0025% in air). BMC Neurosci (2009) 0.88
Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium. Diagn Pathol (2012) 0.80
Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study. PLoS One (2015) 0.76
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer (1994) 5.52
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet (2009) 2.65
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol (2004) 2.40
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol (2006) 1.68
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer (1999) 1.67
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 1.67
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol (2007) 1.64
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res (2001) 1.60
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest (2001) 1.47
Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia. Eur J Vasc Endovasc Surg (2001) 1.47
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1.38
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst (1992) 1.36
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol (2001) 1.33
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Effect of age on the survival of breast cancer patients. Eur J Cancer (1997) 1.30
Continuous positive airway pressure by face mask in acute cardiogenic pulmonary edema. Am J Cardiol (1985) 1.29
Virtual microscopy. J Clin Pathol (2004) 1.24
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol (1998) 1.13
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (1997) 1.10
Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene (2011) 1.10
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
Crystal structure of human erythrocyte carbonic anhydrase C. 3. Molecular structure of the enzyme and of one enzyme-inhibitor complex at 5-5 A resolution. J Mol Biol (1967) 1.05
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J (2001) 1.05
Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology (1992) 1.03
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer (1994) 1.03
Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol (2000) 1.02
Artificial neural networks applied to survival prediction in breast cancer. Oncology (1999) 1.02
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry (1991) 1.02
Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol (1994) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer (2000) 1.01
A regression model for identifying patients at high risk of hypotension, bradycardia and nausea during spinal anesthesia. Acta Anaesthesiol Scand (1992) 1.00
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
Oncogenic point mutations induce altered conformation, redox sensitivity, and DNA binding in the minimal DNA binding domain of avian myeloblastosis virus v-Myb. J Biol Chem (1997) 0.99
Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer (1995) 0.99
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. Br J Cancer (1995) 0.98
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol (1997) 0.98
Pre- and postjunctional modulation of cholinergic neuroeffector transmission by adenine nucleotides. Experiments with agonist and antagonist. Acta Physiol Scand (1985) 0.97
Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest (2001) 0.97
Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br J Cancer (2011) 0.96
STn and prognosis in breast cancer. Oncology (2001) 0.95
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res (2001) 0.95
HER2 oncogene amplification in extramammary Paget's disease. Histopathology (2003) 0.95
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol (1992) 0.94
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer (2001) 0.94
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol (2006) 0.94
Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer (2000) 0.93
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol (1994) 0.93
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. Cancer Res (1996) 0.92
Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control (2010) 0.91
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol (2008) 0.91
Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol (2007) 0.91
Interexaminer reliability in physical examination of the neck. J Manipulative Physiol Ther (1997) 0.90
Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol (2001) 0.90
Analysis of p53 tumor suppressor gene in families with multiple glioma patients. J Neurooncol (2001) 0.90
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia (2006) 0.89
The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Res Treat (2001) 0.89